Approval study DESTINY-Breast04 convinces in new category trastuzumab-deruxtecan: First targeted therapy for metastatic HER2-low breast cancer

被引：0
|
作者：
Fessler, Beate
机构：
来源：
BREAST CARE | 2023年 / 18卷 / 02期
关键词：
D O I：
10.1159/000530539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
    O'Shaughnessy, Joyce
    Basho, Reva
    Lustberg, Maryam
    Lyman, Gary H.
    Prahladan, Manoj
    James, Gareth D.
    Varghese, Della
    Lujan, Flavia
    Tesch, Hans
    CANCER RESEARCH, 2024, 84 (09)
  • [32] Influence of regulatory agency approval of trastuzumab-deruxtecan on the diagnosis of HER2-low status at a reference cancer center in Brazil
    Vianna, Paula Martinez
    Alves, Venancio Avancini Ferreira
    Exman, Pedro
    CANCER RESEARCH, 2024, 84 (09)
  • [33] The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan
    Schreiber, Anna R.
    O'Bryant, Cindy L.
    Kabos, Peter
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) : 1061 - 1069
  • [34] Trastuzumab and Deruxtecan Combination for Survival Benefit in Patients with HER2-low Breast Cancer
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10)
  • [35] A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Zaman, K.
    Modi, S.
    Ohtan, S.
    Lee, C.
    Wang, Y.
    Saxena, K.
    Cameron, D. A.
    SWISS MEDICAL WEEKLY, 2020, : 28S - 29S
  • [36] Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
    Testa, Stefano
    Dickerson, James C.
    Telli, Melinda
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 11
  • [37] Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Ueno, N. T.
    Jacot, W.
    Yamashita, T.
    Sohn, J.
    Tokunaga, E.
    Prat, A.
    Tsurutani, J.
    Park, Y. H.
    Rugo, H. S.
    Xu, B.
    Cardoso, F.
    Mitri, Z.
    Mahtani, R.
    Dunton, K.
    Wang, Y.
    Gambhire, D.
    Cottone, F.
    Harbeck, N.
    Cameron, D. A.
    Modi, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S633
  • [38] Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
    Wolff, Antonio C.
    Mcshane, Lisa M.
    Allison, Kimberly H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (08): : 829 - 831
  • [39] DESTINY-Breast06 continues to explore HR+, HER2-negative metastatic breast cancer beyond DESTINY-Breast04
    Wang, Fei
    Yuan, Peng
    TRANSLATIONAL BREAST CANCER RESEARCH, 2025, 6
  • [40] An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15
    Modi, Shanu
    Salgado, Roberto
    Guarneri, Valentina
    Alagappan, Divi
    Dennis, Natalie
    Newell, Amy Hanlon
    Boran, Aislyn
    Morsli, Ouzna
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2024, 84 (09)
12345